Many large drug developers employ individual groups or teams independently working on discrete steps in the drug development process.
Rare disease biopharma Insmed (NSDQ:INSM) differentiates itself through its focus on patients with rare diseases. To that end, the company works to ensure collaboration between various departments to consider questions related to the applicability of a given molecule and the potential impact it could have on patients.
The company has won FDA approval for Arikayce (amikacin liposome inhalation suspension), a novel treatment of Mycobacterium avium complex (MAC) lung disease in conjunction with an antibacterial drug regimen.
“Many companies speak about patient focus and patient-centricity,” acknowledged Dr. Martina Flammer, the company’s chief medical officer. But often, that focus can be intermittent or can begin midway through development.…